ArticleAntimicrobial agents and chemotherapy2024
ARGONAUT-III and -V: susceptibility of carbapenem-resistant
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Sulbactam-durlobactam and cefiderocol combination treatment ofAntimicrobial agents and chemotherapy · 2026Article
- Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms.Antibiotics (Basel, Switzerland) · 2026Review
- Combining mass spectrometry and machine learning models for predicting Klebsiella pneumoniae antimicrobial resistance: a multicenter experience from clinical isolates in Italy.BMC microbiology · 2026Article
- Bacterial distribution and disease burden analysis in hospital-acquired bloodstream infections according to Diagnosis-Related Groups (DRGs) data.BMC infectious diseases · 2026Article
- Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations.Infection and drug resistance · 2026Review
- Establishing the reference broth microdilution MIC method for cefepime-taniborbactam.Journal of clinical microbiology · 2025Article
- Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletionAntimicrobial agents and chemotherapy · 2025Article
- Impact of porin deletions on cefepime-taniborbactam activity againstAntimicrobial agents and chemotherapy · 2025Article
- ARGONAUT-IV: susceptibility of carbapenemase-producingAntimicrobial agents and chemotherapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Michael R JacobsCase Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-4235-7855
Ayman M AbdelhamedUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Caryn E GoodUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Andrew R MackDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-0131-7996
Christopher R BethelLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA.
Steven MarshallLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA.
Andrea M HujerLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA.
Kristine M HujerLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6344-4141
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227
Vance G FowlerDuke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Daniel D RhoadsCase Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-7636-5191
David A SixVenatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA.ORCID 0000-0002-9013-1711
Greg MoeckVenatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA.ORCID 0000-0001-7827-7227
Tsuyoshi UeharaVenatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA.ORCID 0000-0001-6994-4286
Krisztina M Papp-WallaceCase Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-9976-7898
Robert A BonomoDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MMolecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–Targeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–BLRD VA I01 BX001974BLRD VA I01 BX002872HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI114508HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI104681NIAID NIH HHS R21 AI114508NIAID NIH HHS UM1 AI104681U.S. Department of Veterans Affairs (VA) 1I01BX001974U.S. Department of Veterans Affairs (VA) 1I01BX002872
Abstract
Taniborbactam, a bicyclic boronate β-lactamase inhibitor with activity against
Indexed as
Anti-Bacterial Agentsbeta-Lactamase InhibitorsCefepimeDrug Resistance, Multiple, BacterialKlebsiella pneumoniaeMicrobial Sensitivity TestsPseudomonas aeruginosaAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesBorinic AcidsBoronic AcidsCarbapenemsCarboxylic AcidsCeftazidimeCephalosporinsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasesBorinic AcidsBoronic AcidsCarbapenemsCarboxylic AcidsCefepimeCeftazidimeCephalosporinsDrug Combinationstaniborbactambeta-lactamase inhibitorbicyclic boronatecefepime taniborbactamKlebsiella pneumoniaePseudomonas aeruginosataniborbactam
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.